Agenus advances Phase 3 ROBBIN trial of BOT+BAL in MSS colon cancer
Agenus reported Q2 2026 results and announced an accelerated Phase 3 trial for neoadjuvant colon cancer. The trial is fully funded via a July 2026 private placement and addresses a multi-billion dollar annual market opportunity.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day